EDGAR Filing Documents for 0001213900-24-036802

Form DEF 14A - Other definitive proxy statements:

SEC Accession No. 0001213900-24-036802

Filing Date

2024-04-29

Accepted

2024-04-29 06:17:20

Documents

Period of Report

2024-05-17

Document Format Files

Seq	Description	Document	Type	Size
1	PROXY STATEMENT	ea0204298-01.htm iXBRL	DEF 14A	3292998
6	GRAPHIC	tbarchart_001.jpg	GRAPHIC	322979
7	GRAPHIC	tbarchart_002a.jpg	GRAPHIC	138981
8	GRAPHIC	tbarchart_002b.jpg	GRAPHIC	148866
9	GRAPHIC	tbarchart_002c.jpg	GRAPHIC	145628
10	GRAPHIC	tbarchart_002d.jpg	GRAPHIC	144925
11	GRAPHIC	tcross.jpg	GRAPHIC	2516
12	GRAPHIC	tick.jpg	GRAPHIC	1261
13	GRAPHIC	tick1.jpg	GRAPHIC	1253
14	GRAPHIC	tpiechart_001.jpg	GRAPHIC	252926
15	GRAPHIC	tproxy_001.jpg	GRAPHIC	1053967
16	GRAPHIC	tproxy_002.jpg	GRAPHIC	1183420
17	GRAPHIC	ttimothy_sig.jpg	GRAPHIC	11739
	Complete submission text file	0001213900-24-036802.txt		12427774

Data Files

Seq	Description	Document	Type	Size
2	XBRL SCHEMA FILE	vnda-20240517.xsd	EX-101.SCH	10503
3	XBRL DEFINITION FILE	vnda-20240517_def.xml	EX-101.DEF	8626
4	XBRL LABEL FILE	vnda-20240517_lab.xml	EX-101.LAB	32898
5	XBRL PRESENTATION FILE	vnda-20240517_pre.xml	EX-101.PRE	10201
29	EXTRACTED XBRL INSTANCE DOCUMENT	ea0204298-01_htm.xml	XML	393185

Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037

Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400

Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)